Newron Pharmaceuticals provides update following Type A meeting with the US FDA: Milan, Italy Saturday, July 4, 2026, 10:00 Hrs [IST] Newron Pharmaceuticals S.p.A. (Newron), a bio ...
An analytical guide to cellular optimization, epigenetic switches, and the daily disciplines that preserve youth from the ...
Quantum materials, materials exhibiting physical behavior governed by the laws of quantum mechanics, have proved promising ...
Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced new interim data from its ongoing open-label Phase 1/2 first-in-human study of EPI-321 in ...
Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 ...
SetPoint Medical, a commercial-stage medical technology company dedicated to improving care for people living with chronic ...
Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.
A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...
Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.
You'll come for the hands-on tweaking and wealth of features, and quickly forgive some of the workflow issues when you hear ...
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic ...
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results